Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide. (25th May 2022)

• Record Type: Journal Article
• Authors: Scévola, Sofía; Imaz, Arkaitz; Cottrell, Mackenzie L; Niubo, Jordi; Van Horne, Brian; Tiraboschi, Juan; Saumoy, Maria; Morenilla, Sandra; Soriano, Irene; Kashuba, Angela D M; Podzamczer, Daniel
• Is Part Of: Clinical infectious diseases. Volume 75:Number 11(2022)
• Page Start: 2012
• Page End: 2015
• Publication Date: 2022-05-25
• Subjects: HIV-1 -- antiretroviral therapy -- doravirine -- semen -- cervicovaginal fluid; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac410
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Doravirine (DOR) concentrations and HIV-1 RNA were evaluated in genital fluids from adults with HIV on stable therapy who switched to DOR + FTC/TAF. High protein-unbound DOR concentrations were observed in both seminal plasma and cervicovaginal fluid. DOR + FTC/TAF maintained viral suppression in genital fluids in all but 1 participant.